For the quarter ending 2026-03-31, DTIL had -$11,306K decrease in cash & cash equivalents over the period. -$11,955K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -18,441 | 20,133 | -21,772 | -44,085 |
| Depreciation and amortization | 299 | 345 | 350 | 773 |
| Share-based compensation | 1,549 | 2,041 | 2,386 | 5,759 |
| Impairment charges | - | 36 | - | - |
| (gain) loss on disposal of assets | 4 | -390 | 3 | -34 |
| Issuance of common stock in exchange for services | - | 259 | - | - |
| Non-cash interest expense | 117 | 22 | 18 | 146 |
| Amortization of right-of-use assets | 341 | 333 | 324 | 628 |
| Loss (gain) on changes in other fair value adjustments | -2,951 | -248 | -3 | -2,415 |
| Gain from equity method investment | 0 | -5,370 | -591 | 677 |
| Loss (gain) on change in fair value of warrant liability | - | - | -1,179 | -51 |
| Gain from disposal of business | - | 855 | - | - |
| Amortization of discount on note receivable | 0 | 0 | 231 | 451 |
| Gain on change in fair value of warrant liability | - | 11,129 | - | - |
| Loss on change in fair value of warrant liability | -7,107 | - | - | - |
| Prepaid expenses | 393 | -2,747 | -1,593 | 1,009 |
| Marketable securities | 0 | 5,000 | 0 | -464 |
| Convertible note receivable | - | 0 | 0 | - |
| Accounts receivable | 4,000 | -4 | 4 | -229 |
| Contract asset | 0 | 0 | 0 | -1,469 |
| Other assets and other current assets | -42 | -490 | 106 | 45 |
| Accounts payable | 648 | -1,050 | 220 | 93 |
| Other liabilities and other current liabilities | -1,796 | 2,151 | 528 | -4,441 |
| Deferred revenue | 0 | -26,205 | -9 | -43 |
| Lease liabilities | -357 | -350 | -337 | -633 |
| Net cash used in operating activities | -11,937 | -11,250 | -15,270 | -39,323 |
| Purchases of property, equipment and software | 18 | 19 | 0 | 66 |
| Purchases of intangible assets | 100 | 350 | 0 | 265 |
| Proceeds from sale of equipment | 4 | 44 | 17 | 5 |
| Proceeds from offering of common stock and warrants through underwritten offering, net of issuance costs | - | 69,980 | 0 | 0 |
| Net cash used in investing activities | -114 | -325 | 17 | -326 |
| Proceeds from employee stock purchase plan | 83 | 0 | 78 | 140 |
| Proceeds from issuance of common stock through atm facility, net of issuance cost | 0 | 7,536 | 1,581 | 14,816 |
| Proceeds from issuance of common stock to collaboration partners and licensees | 662 | 0 | 0 | 1,031 |
| Repayment of revolving credit facility | - | 0 | 0 | - |
| Borrowings from term loan debt facility, net of issuance costs paid to lender | - | 0 | 0 | - |
| Net cash provided by financing activities | 745 | 77,516 | 1,659 | 15,987 |
| Net decrease in cash and cash equivalents | -11,306 | 65,941 | -13,594 | -23,662 |
| Cash, cash equivalents, and restricted cash beginning of period | 137,153 | 71,212 | 108,468 | - |
| Cash, cash equivalents, and restricted cash end of period | 125,847 | 137,153 | 71,212 | - |
PRECISION BIOSCIENCES INC (DTIL)
PRECISION BIOSCIENCES INC (DTIL)